Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UVAX-1107
- Development stage
- Phase 1
- Lead developer
- Uvax Bio
- Modality
- Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Recombinant Protein Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
UVAX-1107 is a protein nanoparticle vaccine candidate developed for the prevention of HIV-1 infection. It utilizes Uvax Bio’s proprietary 1c-SApNP vaccine development platform, which generates virus-like particles (VLPs) that closely mimic the target virus in size, shape, and multivalent antigen display. Specifically, UVAX-1107 displays 20 copies of a native-like, prefusion-stabilized trimeric HIV-1 envelope (Env) antigen derived from the BG505 strain. A key innovation in this vaccine is "glycan trimming," an enzymatic process that removes part of the glycan shield from the Env trimer to expose conserved neutralizing epitopes and potentially enhance immune recognition. This approach was recognized as a top emerging technology by IUPAC in 2023. In Phase 1 clinical trials, UVAX-1107 has demonstrated safety and robust immunogenicity with strong IgG antibody responses in all vaccinated subjects[1][2][4][5][6][8].
- Other names
- Uvax HIV-1 vaccine1c-SApNP HIV-1 vaccine
Beyond the preview
Go deeper on UVAX-1107.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UVAX-1107.